FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Vounatsos Michel						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
<u>vounats</u>	SOS IVIICIIO	<u>:1</u>							,						X	Direc	ctor		10% (	Owner		
(Last)	(First) (Middle)				3. D	Date of Earliest Transaction (Month/Day/Year)									X	Offic belov	er (give title w)		Other (specify below)			
BIOGEN	INC.				12/	12/29/2017									Chief Executive Officer							
225 BINI	NEY ST.																					
					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable						
(Street)											`		•	Lir	ne)							
CAMBRIDGE MA 02142															X Form filed by One Reporting Person							
																Form filed by More than One Reporting Person						
(City)	(SI	ate) (	Zip)																			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)					r) Ex	A. Deemed xecution Date, any Month/Day/Year)					ties Acquired (A) o I Of (D) (Instr. 3, 4			and 5) Secur		icially d Following	6. Owner Form: I (D) or Ir (I) (Inst	irect direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										v	Amount	(A)	) or )	Price		Transaction(s) (Instr. 3 and 4)				(111311.4)		
Common Stock 12/29/2					2017						780		A \$320		0.55 4,879		379.458	Ι	)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security  Date (Month/Day/Year)  Execution Date, if any (Month/Day/Year)			4. Transa Code ( 8)		5. Nu of Deriv Secul Acqui (A) oi Dispo of (D) (Instr and 5	ative rities ired osed	Expiration (Month/E	Date Expiration  Expiration Date (Month/Day/Year)  Date Expiration  Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of			ce of ative rity . 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owi Fori Dire or Ii (I) (I	nership n: ct (D) ndirect nstr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

## **Explanation of Responses:**

1. Purchase pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

/s/ Suzanne Murray, Attorney in Fact for Michel Vounatsos

01/02/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.